Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytek Biosciences Inc before investing.

In this article, we go over a few key elements for understanding Cytek Biosciences Inc’s stock price such as:

• Cytek Biosciences Inc’s current stock price and volume
• Why Cytek Biosciences Inc’s stock price changed recently
• Upgrades and downgrades for CTKB from analysts
• CTKB’s stock price momentum as measured by its relative strength

About Cytek Biosciences Inc (CTKB)

Before we jump into Cytek Biosciences Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Want to learn more about Cytek Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cytek Biosciences Inc.

Cytek Biosciences Inc’s Stock Price as of Market Close

As of September 05, 2024, 4:00 PM, CST, Cytek Biosciences Inc’s stock price was $5.44.

Cytek Biosciences Inc is up 4.02% from its previous closing price of $5.23.

During the last market session, Cytek Biosciences Inc’s stock traded between $5.20 and $5.42. Currently, there are 131.44 million shares of Cytek Biosciences Inc stock available for purchase.

Unfortunately, Cytek Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Cytek Biosciences Inc Stock Price History

Cytek Biosciences Inc’s (CTKB) price is currently down 5.23% so far this month.

During the month of September, Cytek Biosciences Inc’s stock price has reached a high of $5.77 and a low of $5.20.

Over the last year, Cytek Biosciences Inc has hit prices as high as $9.87 and as low as $3.80. Year to date, Cytek Biosciences Inc’s stock is down 46.72%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cytek Biosciences Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of September 04, 2024,, no analysts have changed their rating of Cytek Biosciences Inc’s stock over the last month.

Additionally, you'll want to evaluate Cytek Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cytek Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cytek Biosciences Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cytek Biosciences Inc (CTKB) by visiting AAII Stock Evaluator.

Relative Price Strength of Cytek Biosciences Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2024, Cytek Biosciences Inc has a weighted four-quarter relative price strength of -11.26%, which translates to a Momentum Score of 30 and is considered to be Weak.

Want to learn more about how Cytek Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cytek Biosciences Inc Stock Price: Bottom Line

As of September 5, 2024, Cytek Biosciences Inc’s stock price is $5.44, which is up 4.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cytek Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.